TY  - GEN
AU  - Pockros,Paul J
AU  - Nelson,David
AU  - Godofsky,Eliot
AU  - Rodriguez-Torres,Maribel
AU  - Everson,Gregory T
AU  - Fried,Michael W
AU  - Ghalib,Reem
AU  - Harrison,Stephen
AU  - Nyberg,Lisa
AU  - Shiffman,Mitchell L
AU  - Najera,Isabel
AU  - Chan,Anna
AU  - Hill,George
TI  - R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin
SN  - 1527-3350
PY  - 2008///0905
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Alanine Transaminase
KW  - blood
KW  - Antiviral Agents
KW  - administration & dosage
KW  - Cytidine
KW  - analogs & derivatives
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Drug Resistance, Viral
KW  - Drug Synergism
KW  - Drug Therapy, Combination
KW  - Female
KW  - Hepacivirus
KW  - enzymology
KW  - Humans
KW  - Interferon alpha-2
KW  - Interferon-alpha
KW  - adverse effects
KW  - Male
KW  - Middle Aged
KW  - Neutropenia
KW  - chemically induced
KW  - Nucleosides
KW  - Polyethylene Glycols
KW  - Prodrugs
KW  - RNA, Viral
KW  - antagonists & inhibitors
KW  - Recombinant Proteins
KW  - Ribavirin
KW  - Treatment Outcome
KW  - Viral Load
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1002/hep.22357
ER  -